Insider transactions

EDGAR

Kailera Therapeutics, Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-22.

Open-market purchases (code P)
5 transactions, 20,421,876 shares
Sum of shares × price per share: 326,750,016
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–48 of 48

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-09-07 Filed 2026-09-09Nicholson Nur Officer: Chief Technology Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (220,000) — exercise price 16.23
Acquired (A)220,0000—220,000Direct (D) No
F1
  • F1 The options vest and become exercisable as to 25% of the underlying shares on August 31, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date.
Open filing 0001193125-26-386782 Read from the filing’s XML Dispute this row
2026-07-06 Filed 2026-07-08Tregoning Kathleen Officer: See Remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (175,000) — exercise price 23.30
Acquired (A)175,0000—175,000Direct (D) No
F1
  • F1 The options vest and become exercisable as to 25% of the underlying shares on June 29, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date.
Open filing 0001193125-26-298558 Read from the filing’s XML Dispute this row
2026-06-09 Filed 2026-06-11Renaud Ronald C JR Director · Officer: CEO President
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)38,0945.25
199,993.5

Derived: shares × price per share. Exact value 199993.50.

38,094Direct (D) No— Open filing 0001193125-26-267493 Read from the filing’s XML Dispute this row
2026-06-09 Filed 2026-06-11Renaud Ronald C JR Director · Officer: CEO President
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (right to buy) — underlying Common Stock (38,094) — exercise price 5.25
Disposed (D)38,0940—817,826Direct (D) No
F1
  • F1 The options vested and became exercisable as to 33% of the total shares on September 9, 2025 and thereafter in 24 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.
Open filing 0001193125-26-267493 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% owner
C

Conversion of derivative security

Common Stock
Acquired (A)9,477,719——9,477,719Direct (D) No
F2
  • F2 The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the Preferred Stock) of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.
Open filing 0001104659-26-046276 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% owner
C

Conversion of derivative security

Common Stock
Acquired (A)2,034,133——2,034,133Direct (D) No
F2
  • F2 The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the Preferred Stock) of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.
Open filing 0001104659-26-046276 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% owner
C

Conversion of derivative security

Derivative security: Series A-2 convertible preferred stock — underlying Common Stock (9,477,719)
Disposed (D)4,968,7890—0Direct (D) No
F2
  • F2 The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the Preferred Stock) of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.
Open filing 0001104659-26-046276 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% owner
C

Conversion of derivative security

Derivative security: Series A-2 convertible non-voting preferred stock — underlying Common Stock (2,034,133)
Disposed (D)708,8140—0Direct (D) No
F2
  • F2 The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the Preferred Stock) of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.
Open filing 0001104659-26-046276 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22RTW INVESTMENTS, LP 10% ownerWONG RODERICK 10% owner
C

Conversion of derivative security

Common Stock
Acquired (A)10,276,820——10,276,820Indirect (I) See footnoteNo
F1, F2
  • F1 Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-1 basis and had no expiration date.
  • F2 Held by certain affiliated funds managed by RTW Investments, LP (RTW). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of RTW. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, except to the extent of their pecuniary interest therein.
Open filing 0001231919-26-000390 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22RTW INVESTMENTS, LP 10% ownerWONG RODERICK 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)500,00016
8,000,000

Derived: shares × price per share. Exact value 8000000.

10,776,820Indirect (I) See footnoteNo
F2
  • F2 Held by certain affiliated funds managed by RTW Investments, LP (RTW). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of RTW. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, except to the extent of their pecuniary interest therein.
Open filing 0001231919-26-000390 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22RTW INVESTMENTS, LP 10% ownerWONG RODERICK 10% owner
C

Conversion of derivative security

Derivative security: Series A Preferred Stock — underlying Common Stock (8,250,000)
Disposed (D)8,250,000——0Indirect (I) See footnoteNo
F1, F2
  • F1 Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-1 basis and had no expiration date.
  • F2 Held by certain affiliated funds managed by RTW Investments, LP (RTW). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of RTW. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, except to the extent of their pecuniary interest therein.
Open filing 0001231919-26-000390 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22RTW INVESTMENTS, LP 10% ownerWONG RODERICK 10% owner
C

Conversion of derivative security

Derivative security: Series B Preferred Stock — underlying Common Stock (2,026,820)
Disposed (D)2,026,820——0Indirect (I) See footnoteNo
F1, F2
  • F1 Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-1 basis and had no expiration date.
  • F2 Held by certain affiliated funds managed by RTW Investments, LP (RTW). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of RTW. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, except to the extent of their pecuniary interest therein.
Open filing 0001231919-26-000390 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-20Koppel Adam Director · 10% owner
C

Conversion of derivative security

Common Stock
Acquired (A)16,875,000——16,875,000Indirect (I) See footnotesNo
F1, F4, F5
  • F1 Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date.
  • F4 Represents securities held directly by BCLS Fund IV Investments, LP (BCLS Fund IV Investments).
  • F5 Dr. Koppel is a Partner of Bain Capital Life Sciences Investors, LLC (BCLSI). BCLSI is the ultimate general partner of BCLS Fund IV Investments. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Open filing 0001193125-26-164407 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-20Koppel Adam Director · 10% owner
C

Conversion of derivative security

Common Stock
Acquired (A)4,145,768——21,020,768Indirect (I) See footnotesNo
F2, F4, F5
  • F2 Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date.
  • F4 Represents securities held directly by BCLS Fund IV Investments, LP (BCLS Fund IV Investments).
  • F5 Dr. Koppel is a Partner of Bain Capital Life Sciences Investors, LLC (BCLSI). BCLSI is the ultimate general partner of BCLS Fund IV Investments. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Open filing 0001193125-26-164407 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-20Koppel Adam Director · 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)1,562,50016.00
25,000,000

Derived: shares × price per share. Exact value 25000000.00.

22,583,268Indirect (I) See footnotesNo
F4, F5
  • F4 Represents securities held directly by BCLS Fund IV Investments, LP (BCLS Fund IV Investments).
  • F5 Dr. Koppel is a Partner of Bain Capital Life Sciences Investors, LLC (BCLSI). BCLSI is the ultimate general partner of BCLS Fund IV Investments. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Open filing 0001193125-26-164407 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-20Koppel Adam Director · 10% owner
C

Conversion of derivative security

Derivative security: Series A-1 Preferred Stock — underlying Common Stock (16,875,000)
Disposed (D)16,875,0000.00
0

Derived: shares × price per share. Exact value 0.00.

0Indirect (I) See footnotesNo
F1, F4, F5
  • F1 Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date.
  • F4 Represents securities held directly by BCLS Fund IV Investments, LP (BCLS Fund IV Investments).
  • F5 Dr. Koppel is a Partner of Bain Capital Life Sciences Investors, LLC (BCLSI). BCLSI is the ultimate general partner of BCLS Fund IV Investments. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Open filing 0001193125-26-164407 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-20Koppel Adam Director · 10% owner
C

Conversion of derivative security

Derivative security: Series B Preferred Stock — underlying Common Stock (4,145,768)
Disposed (D)4,145,7680.00
0

Derived: shares × price per share. Exact value 0.00.

0Indirect (I) See footnotesNo
F2, F4, F5
  • F2 Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date.
  • F4 Represents securities held directly by BCLS Fund IV Investments, LP (BCLS Fund IV Investments).
  • F5 Dr. Koppel is a Partner of Bain Capital Life Sciences Investors, LLC (BCLSI). BCLSI is the ultimate general partner of BCLS Fund IV Investments. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Open filing 0001193125-26-164407 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-20Bain Capital Life Sciences Investors, LLC 10% ownerBain Capital Life Sciences IV General Partner, LLC 10% ownerBain Capital Life Sciences Fund IV, L.P. 10% ownerBCLS Fund IV Investments GP, LLC 10% ownerBCLS Fund IV Investments, L.P. 10% owner
C

Conversion of derivative security

Common Stock
Acquired (A)16,875,000——16,875,000Indirect (I) See footnotesNo
F1, F3, F4
  • F1 Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date.
  • F3 Represents securities held directly by BCLS Fund IV Investments, LP (BCLS Fund IV Investments).
  • F4 Bain Capital Life Sciences Investors, LLC (BCLSI) is the manager of Bain Capital Life Sciences IV General Partner, LLC (BCLS Fund IV GP), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. (BCLS Fund IV), which is the managing member of BCLS Fund IV Investments GP, LLC (BCLS Fund IV Investments GP), which is the general partner of BCLS Fund IV Investments. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Open filing 0001193125-26-164389 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-20Bain Capital Life Sciences Investors, LLC 10% ownerBain Capital Life Sciences IV General Partner, LLC 10% ownerBain Capital Life Sciences Fund IV, L.P. 10% ownerBCLS Fund IV Investments GP, LLC 10% ownerBCLS Fund IV Investments, L.P. 10% owner
C

Conversion of derivative security

Common Stock
Acquired (A)4,145,768——21,020,768Indirect (I) See footnotesNo
F2, F3, F4
  • F2 Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date.
  • F3 Represents securities held directly by BCLS Fund IV Investments, LP (BCLS Fund IV Investments).
  • F4 Bain Capital Life Sciences Investors, LLC (BCLSI) is the manager of Bain Capital Life Sciences IV General Partner, LLC (BCLS Fund IV GP), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. (BCLS Fund IV), which is the managing member of BCLS Fund IV Investments GP, LLC (BCLS Fund IV Investments GP), which is the general partner of BCLS Fund IV Investments. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Open filing 0001193125-26-164389 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-20Bain Capital Life Sciences Investors, LLC 10% ownerBain Capital Life Sciences IV General Partner, LLC 10% ownerBain Capital Life Sciences Fund IV, L.P. 10% ownerBCLS Fund IV Investments GP, LLC 10% ownerBCLS Fund IV Investments, L.P. 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)1,562,50016.00
25,000,000

Derived: shares × price per share. Exact value 25000000.00.

22,583,268Indirect (I) See footnotesNo
F3, F4
  • F3 Represents securities held directly by BCLS Fund IV Investments, LP (BCLS Fund IV Investments).
  • F4 Bain Capital Life Sciences Investors, LLC (BCLSI) is the manager of Bain Capital Life Sciences IV General Partner, LLC (BCLS Fund IV GP), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. (BCLS Fund IV), which is the managing member of BCLS Fund IV Investments GP, LLC (BCLS Fund IV Investments GP), which is the general partner of BCLS Fund IV Investments. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Open filing 0001193125-26-164389 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-20Bain Capital Life Sciences Investors, LLC 10% ownerBain Capital Life Sciences IV General Partner, LLC 10% ownerBain Capital Life Sciences Fund IV, L.P. 10% ownerBCLS Fund IV Investments GP, LLC 10% ownerBCLS Fund IV Investments, L.P. 10% owner
C

Conversion of derivative security

Derivative security: Series A-1 Preferred Stock — underlying Common Stock (16,875,000)
Disposed (D)16,875,0000—0Indirect (I) See footnotesNo
F1, F3, F4
  • F1 Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date.
  • F3 Represents securities held directly by BCLS Fund IV Investments, LP (BCLS Fund IV Investments).
  • F4 Bain Capital Life Sciences Investors, LLC (BCLSI) is the manager of Bain Capital Life Sciences IV General Partner, LLC (BCLS Fund IV GP), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. (BCLS Fund IV), which is the managing member of BCLS Fund IV Investments GP, LLC (BCLS Fund IV Investments GP), which is the general partner of BCLS Fund IV Investments. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Open filing 0001193125-26-164389 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-20Bain Capital Life Sciences Investors, LLC 10% ownerBain Capital Life Sciences IV General Partner, LLC 10% ownerBain Capital Life Sciences Fund IV, L.P. 10% ownerBCLS Fund IV Investments GP, LLC 10% ownerBCLS Fund IV Investments, L.P. 10% owner
C

Conversion of derivative security

Derivative security: Series B Preferred Stock — underlying Common Stock (4,145,768)
Disposed (D)4,145,7680—0Indirect (I) See footnotesNo
F2, F3, F4
  • F2 Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date.
  • F3 Represents securities held directly by BCLS Fund IV Investments, LP (BCLS Fund IV Investments).
  • F4 Bain Capital Life Sciences Investors, LLC (BCLSI) is the manager of Bain Capital Life Sciences IV General Partner, LLC (BCLS Fund IV GP), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. (BCLS Fund IV), which is the managing member of BCLS Fund IV Investments GP, LLC (BCLS Fund IV Investments GP), which is the general partner of BCLS Fund IV Investments. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Open filing 0001193125-26-164389 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-20Kaplan Andrew T. Director · 10% owner
C

Conversion of derivative security

Common Stock
Acquired (A)17,857,143——17,857,143Indirect (I) See footnotesNo
F1, F3, F4
  • F1 Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date.
  • F3 Represents securities held directly by BCPE Perseus Investor, LP (BCPE Perseus).
  • F4 Mr. Kaplan is a Partner of Bain Capital Investors, LLC (BCI). BCI is the ultimate general partner of BCPE Perseus. As a result, Mr. Kaplan may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. Mr. Kaplan disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Open filing 0001193125-26-164388 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-20Kaplan Andrew T. Director · 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)8,398,43816.00
134,375,008

Derived: shares × price per share. Exact value 134375008.00.

26,255,581Indirect (I) See footnotesNo
F3, F4
  • F3 Represents securities held directly by BCPE Perseus Investor, LP (BCPE Perseus).
  • F4 Mr. Kaplan is a Partner of Bain Capital Investors, LLC (BCI). BCI is the ultimate general partner of BCPE Perseus. As a result, Mr. Kaplan may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. Mr. Kaplan disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Open filing 0001193125-26-164388 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-20Kaplan Andrew T. Director · 10% owner
C

Conversion of derivative security

Derivative security: Series B Preferred Stock — underlying Common Stock (17,857,143)
Disposed (D)17,857,1430—0Indirect (I) See footnotesNo
F1, F3, F4
  • F1 Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date.
  • F3 Represents securities held directly by BCPE Perseus Investor, LP (BCPE Perseus).
  • F4 Mr. Kaplan is a Partner of Bain Capital Investors, LLC (BCI). BCI is the ultimate general partner of BCPE Perseus. As a result, Mr. Kaplan may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. Mr. Kaplan disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Open filing 0001193125-26-164388 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-20BAIN CAPITAL INVESTORS LLC 10% ownerBain Capital XIV General Partner, LLC 10% ownerBain Capital Fund XIV, L.P. 10% ownerBCPE Perseus Investor GP, LLC 10% ownerBCPE Perseus Investor, LP 10% owner
C

Conversion of derivative security

Common Stock
Acquired (A)17,857,143——17,857,143Indirect (I) See footnotesNo
F1, F2, F3
  • F1 Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date.
  • F2 Represents securities held directly by BCPE Perseus Investor, LP (BCPE Perseus).
  • F3 Bain Capital Investors, LLC (BCI) is the manager of Bain Capital XIV General Partner, LLC (BCPE Fund XIV GP), which is the general partner of Bain Capital Fund XIV, L.P. (BCPE Fund XIV), which is the managing member of BCPE Perseus Investor GP, LLC (BCPE Perseus GP), which is the general partner of BCPE Perseus. As a result, each of BCI, BCPE Fund XIV GP, BCPE Fund XIV and BCPE Perseus GP may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. BCI, BCPE Fund XIV GP, BCPE Fund XIV and BCPE Perseus GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Open filing 0001193125-26-164417 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-20BAIN CAPITAL INVESTORS LLC 10% ownerBain Capital XIV General Partner, LLC 10% ownerBain Capital Fund XIV, L.P. 10% ownerBCPE Perseus Investor GP, LLC 10% ownerBCPE Perseus Investor, LP 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)8,398,43816.00
134,375,008

Derived: shares × price per share. Exact value 134375008.00.

26,255,581Indirect (I) See footnotesNo
F2, F3
  • F2 Represents securities held directly by BCPE Perseus Investor, LP (BCPE Perseus).
  • F3 Bain Capital Investors, LLC (BCI) is the manager of Bain Capital XIV General Partner, LLC (BCPE Fund XIV GP), which is the general partner of Bain Capital Fund XIV, L.P. (BCPE Fund XIV), which is the managing member of BCPE Perseus Investor GP, LLC (BCPE Perseus GP), which is the general partner of BCPE Perseus. As a result, each of BCI, BCPE Fund XIV GP, BCPE Fund XIV and BCPE Perseus GP may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. BCI, BCPE Fund XIV GP, BCPE Fund XIV and BCPE Perseus GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Open filing 0001193125-26-164417 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-20BAIN CAPITAL INVESTORS LLC 10% ownerBain Capital XIV General Partner, LLC 10% ownerBain Capital Fund XIV, L.P. 10% ownerBCPE Perseus Investor GP, LLC 10% ownerBCPE Perseus Investor, LP 10% owner
C

Conversion of derivative security

Derivative security: Series B Preferred Stock — underlying Common Stock (17,857,143)
Disposed (D)17,857,1430—0Indirect (I) See footnotesNo
F1, F2, F3
  • F1 Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date.
  • F2 Represents securities held directly by BCPE Perseus Investor, LP (BCPE Perseus).
  • F3 Bain Capital Investors, LLC (BCI) is the manager of Bain Capital XIV General Partner, LLC (BCPE Fund XIV GP), which is the general partner of Bain Capital Fund XIV, L.P. (BCPE Fund XIV), which is the managing member of BCPE Perseus Investor GP, LLC (BCPE Perseus GP), which is the general partner of BCPE Perseus. As a result, each of BCI, BCPE Fund XIV GP, BCPE Fund XIV and BCPE Perseus GP may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. BCI, BCPE Fund XIV GP, BCPE Fund XIV and BCPE Perseus GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Open filing 0001193125-26-164417 Read from the filing’s XML Dispute this row
2026-04-16 Filed 2026-04-20Coleman Jamie Beth Officer: Chief Commercial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (75,000) — exercise price 16
Acquired (A)75,0000—75,000Direct (D) No
F1
  • F1 The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date.
Open filing 0001193125-26-164264 Read from the filing’s XML Dispute this row
2026-04-16 Filed 2026-04-20Coleman Jamie Beth Officer: Chief Commercial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (75,000) — exercise price 16
Acquired (A)75,0000—75,000Direct (D) No
F2
  • F2 The options vest and become exercisable, if at all, as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the Performance Measurement Period), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date.
Open filing 0001193125-26-164264 Read from the filing’s XML Dispute this row
2026-04-16 Filed 2026-04-20Pagan Douglas W. Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (100,000) — exercise price 16
Acquired (A)100,0000—100,000Direct (D) No
F1
  • F1 The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date.
Open filing 0001193125-26-164210 Read from the filing’s XML Dispute this row
2026-04-16 Filed 2026-04-20Pagan Douglas W. Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (100,000) — exercise price 16
Acquired (A)100,0000—100,000Direct (D) No
F2
  • F2 The options vest and become exercisable, if at all, as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the Performance Measurement Period), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date.
Open filing 0001193125-26-164210 Read from the filing’s XML Dispute this row
2026-04-16 Filed 2026-04-20Burgess Paul D. Officer: See Remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (100,000) — exercise price 16
Acquired (A)100,0000—100,000Direct (D) No
F1
  • F1 The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date.
Open filing 0001193125-26-164275 Read from the filing’s XML Dispute this row
2026-04-16 Filed 2026-04-20Burgess Paul D. Officer: See Remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (100,000) — exercise price 16
Acquired (A)100,0000—100,000Direct (D) No
F2
  • F2 The options vest and become exercisable, if at all, as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the Performance Measurement Period), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date.
Open filing 0001193125-26-164275 Read from the filing’s XML Dispute this row
2026-04-16 Filed 2026-04-20Akamine Scott Officer: Chief Legal Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (60,000) — exercise price 16
Acquired (A)60,0000—60,000Direct (D) No
F1
  • F1 The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date.
Open filing 0001193125-26-164306 Read from the filing’s XML Dispute this row
2026-04-16 Filed 2026-04-20Akamine Scott Officer: Chief Legal Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (60,000) — exercise price 16
Acquired (A)60,0000—60,000Direct (D) No
F2
  • F2 The options vest and become exercisable, if at all, as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the Performance Measurement Period), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date.
Open filing 0001193125-26-164306 Read from the filing’s XML Dispute this row
2026-04-16 Filed 2026-04-20Clyburn Frank Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (38,300) — exercise price 16
Acquired (A)38,3000—38,300Direct (D) No
F1
  • F1 The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date.
Open filing 0001193125-26-164224 Read from the filing’s XML Dispute this row
2026-04-16 Filed 2026-04-20Koppel Adam Director · 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (38,300) — exercise price 16.00
Acquired (A)38,3000.00
0

Derived: shares × price per share. Exact value 0.00.

38,300Direct (D) No
F3
  • F3 The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to Dr. Koppel's continued service through each such vesting date.
Open filing 0001193125-26-164407 Read from the filing’s XML Dispute this row
2026-04-16 Filed 2026-04-20Renaud Ronald C JR Director · Officer: CEO President
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (300,000) — exercise price 16
Acquired (A)300,0000—300,000Direct (D) No
F1
  • F1 The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date.
Open filing 0001193125-26-164299 Read from the filing’s XML Dispute this row
2026-04-16 Filed 2026-04-20Renaud Ronald C JR Director · Officer: CEO President
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (300,000) — exercise price 16
Acquired (A)300,0000—300,000Direct (D) No
F2
  • F2 The options vest and become exercisable, if at all, as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the Performance Measurement Period), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date.
Open filing 0001193125-26-164299 Read from the filing’s XML Dispute this row
2026-04-16 Filed 2026-04-20MACKAY MARTIN Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (38,300) — exercise price 16
Acquired (A)38,3000—38,300Direct (D) No
F1
  • F1 The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date.
Open filing 0001193125-26-164253 Read from the filing’s XML Dispute this row
2026-04-16 Filed 2026-04-20Cloghessy Paula Officer: Chief People Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (60,000) — exercise price 16
Acquired (A)60,0000—60,000Direct (D) No
F1
  • F1 The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date.
Open filing 0001193125-26-164307 Read from the filing’s XML Dispute this row
2026-04-16 Filed 2026-04-20Cloghessy Paula Officer: Chief People Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (60,000) — exercise price 16
Acquired (A)60,0000—60,000Direct (D) No
F2
  • F2 The options vest and become exercisable, if at all, as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the Performance Measurement Period), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date.
Open filing 0001193125-26-164307 Read from the filing’s XML Dispute this row
2026-04-16 Filed 2026-04-20Kaplan Andrew T. Director · 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (38,300) — exercise price 16.00
Acquired (A)38,3000—38,300Direct (D) No
F2
  • F2 The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to Mr. Kaplan's continued service through each such vesting date.
Open filing 0001193125-26-164388 Read from the filing’s XML Dispute this row
2026-04-16 Filed 2026-04-20Hite Christopher Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (38,300) — exercise price 16
Acquired (A)38,3000—38,300Direct (D) No
F1
  • F1 The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date.
Open filing 0001193125-26-164226 Read from the filing’s XML Dispute this row
2026-04-16 Filed 2026-04-20Wasserman Scott M. Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (100,000) — exercise price 16
Acquired (A)100,0000—100,000Direct (D) No
F1
  • F1 The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date.
Open filing 0001193125-26-164243 Read from the filing’s XML Dispute this row
2026-04-16 Filed 2026-04-20Wasserman Scott M. Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (100,000) — exercise price 16
Acquired (A)100,0000—100,000Direct (D) No
F2
  • F2 The options vest and become exercisable, if at all, as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the Performance Measurement Period), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date.
Open filing 0001193125-26-164243 Read from the filing’s XML Dispute this row
2026-04-16 Filed 2026-04-20MILLIGAN JOHN F Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (38,300) — exercise price 16
Acquired (A)38,3000—38,300Direct (D) No
F1
  • F1 The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date.
Open filing 0001193125-26-164271 Read from the filing’s XML Dispute this row

Latest reported holdings

What each reporting owner last said they hold, as of the date shown. A transaction not yet filed is not in it.

Latest reported holdings
Reporting ownerSecurityShares owned afterDirect or indirectSource
Akamine Scott Officer: Chief Legal OfficerStock Option (right to buy) Derivative security · underlying Common Stock60,000D As of 2026-04-16 Open filing 4
BAIN CAPITAL INVESTORS LLC 10% ownerSeries B Preferred Stock Derivative security · underlying Common Stock0I See footnotesAs of 2026-04-20 Open filing 4
BAIN CAPITAL INVESTORS LLC 10% ownerCommon Stock 26,255,581I See footnotesAs of 2026-04-20 Open filing 4
BCLS Fund IV Investments GP, LLC 10% ownerSeries A-1 Preferred Stock Derivative security · underlying Common Stock0I See footnotesAs of 2026-04-20 Open filing 4
BCLS Fund IV Investments GP, LLC 10% ownerSeries B Preferred Stock Derivative security · underlying Common Stock0I See footnotesAs of 2026-04-20 Open filing 4
BCLS Fund IV Investments GP, LLC 10% ownerCommon Stock 22,583,268I See footnotesAs of 2026-04-20 Open filing 4
BCLS Fund IV Investments, L.P. 10% ownerSeries A-1 Preferred Stock Derivative security · underlying Common Stock0I See footnotesAs of 2026-04-20 Open filing 4
BCLS Fund IV Investments, L.P. 10% ownerSeries B Preferred Stock Derivative security · underlying Common Stock0I See footnotesAs of 2026-04-20 Open filing 4
BCLS Fund IV Investments, L.P. 10% ownerCommon Stock 22,583,268I See footnotesAs of 2026-04-20 Open filing 4
BCPE Perseus Investor GP, LLC 10% ownerSeries B Preferred Stock Derivative security · underlying Common Stock0I See footnotesAs of 2026-04-20 Open filing 4
BCPE Perseus Investor GP, LLC 10% ownerCommon Stock 26,255,581I See footnotesAs of 2026-04-20 Open filing 4
BCPE Perseus Investor, LP 10% ownerSeries B Preferred Stock Derivative security · underlying Common Stock0I See footnotesAs of 2026-04-20 Open filing 4
BCPE Perseus Investor, LP 10% ownerCommon Stock 26,255,581I See footnotesAs of 2026-04-20 Open filing 4
Bain Capital Fund XIV, L.P. 10% ownerSeries B Preferred Stock Derivative security · underlying Common Stock0I See footnotesAs of 2026-04-20 Open filing 4
Bain Capital Fund XIV, L.P. 10% ownerCommon Stock 26,255,581I See footnotesAs of 2026-04-20 Open filing 4
Bain Capital Life Sciences Fund IV, L.P. 10% ownerSeries A-1 Preferred Stock Derivative security · underlying Common Stock0I See footnotesAs of 2026-04-20 Open filing 4
Bain Capital Life Sciences Fund IV, L.P. 10% ownerSeries B Preferred Stock Derivative security · underlying Common Stock0I See footnotesAs of 2026-04-20 Open filing 4
Bain Capital Life Sciences Fund IV, L.P. 10% ownerCommon Stock 22,583,268I See footnotesAs of 2026-04-20 Open filing 4
Bain Capital Life Sciences IV General Partner, LLC 10% ownerSeries A-1 Preferred Stock Derivative security · underlying Common Stock0I See footnotesAs of 2026-04-20 Open filing 4
Bain Capital Life Sciences IV General Partner, LLC 10% ownerSeries B Preferred Stock Derivative security · underlying Common Stock0I See footnotesAs of 2026-04-20 Open filing 4
Bain Capital Life Sciences IV General Partner, LLC 10% ownerCommon Stock 22,583,268I See footnotesAs of 2026-04-20 Open filing 4
Bain Capital Life Sciences Investors, LLC 10% ownerSeries A-1 Preferred Stock Derivative security · underlying Common Stock0I See footnotesAs of 2026-04-20 Open filing 4
Bain Capital Life Sciences Investors, LLC 10% ownerSeries B Preferred Stock Derivative security · underlying Common Stock0I See footnotesAs of 2026-04-20 Open filing 4
Bain Capital Life Sciences Investors, LLC 10% ownerCommon Stock 22,583,268I See footnotesAs of 2026-04-20 Open filing 4
Bain Capital XIV General Partner, LLC 10% ownerSeries B Preferred Stock Derivative security · underlying Common Stock0I See footnotesAs of 2026-04-20 Open filing 4
Bain Capital XIV General Partner, LLC 10% ownerCommon Stock 26,255,581I See footnotesAs of 2026-04-20 Open filing 4
Burgess Paul D. Officer: See RemarksStock Option (right to buy) Derivative security · underlying Common Stock100,000D As of 2026-04-16 Open filing 4
Cloghessy Paula Officer: Chief People OfficerStock Option (right to buy) Derivative security · underlying Common Stock60,000D As of 2026-04-16 Open filing 4
Clyburn Frank DirectorStock Option (right to buy) Derivative security · underlying Common Stock38,300D As of 2026-04-16 Open filing 4
Coleman Jamie Beth Officer: Chief Commercial OfficerStock Option (right to buy) Derivative security · underlying Common Stock75,000D As of 2026-04-16 Open filing 4
Hite Christopher DirectorStock Option (right to buy) Derivative security · underlying Common Stock38,300D As of 2026-04-16 Open filing 4
Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% ownerSeries A-2 convertible non-voting preferred stock Derivative security · underlying Common Stock0D As of 2026-04-20 Open filing 4
Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% ownerSeries A-2 convertible preferred stock Derivative security · underlying Common Stock0D As of 2026-04-20 Open filing 4
Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% ownerCommon Stock 1I By Hengrui (USA) Ltd.As of 2026-04-22 Open filing 4
Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% ownerCommon Stock 2,034,133D As of 2026-04-20 Open filing 4
Kaplan Andrew T. Director · 10% ownerSeries B Preferred Stock Derivative security · underlying Common Stock0I See footnotesAs of 2026-04-20 Open filing 4
Kaplan Andrew T. Director · 10% ownerStock Option (right to buy) Derivative security · underlying Common Stock38,300D As of 2026-04-16 Open filing 4
Kaplan Andrew T. Director · 10% ownerCommon Stock 26,255,581I See footnotesAs of 2026-04-20 Open filing 4
Koppel Adam Director · 10% ownerSeries A-1 Preferred Stock Derivative security · underlying Common Stock0I See footnotesAs of 2026-04-20 Open filing 4
Koppel Adam Director · 10% ownerSeries B Preferred Stock Derivative security · underlying Common Stock0I See footnotesAs of 2026-04-20 Open filing 4
Koppel Adam Director · 10% ownerStock Option (right to buy) Derivative security · underlying Common Stock38,300D As of 2026-04-16 Open filing 4
Koppel Adam Director · 10% ownerCommon Stock 22,583,268I See footnotesAs of 2026-04-20 Open filing 4
MACKAY MARTIN DirectorStock Option (right to buy) Derivative security · underlying Common Stock38,300D As of 2026-04-16 Open filing 4
MILLIGAN JOHN F DirectorStock Option (right to buy) Derivative security · underlying Common Stock38,300D As of 2026-04-16 Open filing 4
Nicholson Nur Officer: Chief Technology OfficerStock Option (right to buy) Derivative security · underlying Common Stock220,000D As of 2026-09-07 Open filing 4
Pagan Douglas W. Officer: Chief Financial OfficerStock Option (right to buy) Derivative security · underlying Common Stock100,000D As of 2026-04-16 Open filing 4
RTW INVESTMENTS, LP 10% ownerSeries A Preferred Stock Derivative security · underlying Common Stock0I See footnoteAs of 2026-04-20 Open filing 4
RTW INVESTMENTS, LP 10% ownerSeries B Preferred Stock Derivative security · underlying Common Stock0I See footnoteAs of 2026-04-20 Open filing 4
RTW INVESTMENTS, LP 10% ownerCommon Stock 10,776,820I See footnoteAs of 2026-04-20 Open filing 4
Renaud Ronald C JR Director · Officer: CEO PresidentStock Option (right to buy) Derivative security · underlying Common Stock817,826D As of 2026-06-09 Open filing 4
Renaud Ronald C JR Director · Officer: CEO PresidentCommon Stock 38,094D As of 2026-06-09 Open filing 4
Tregoning Kathleen Officer: See RemarksStock Option (right to buy) Derivative security · underlying Common Stock175,000D As of 2026-07-06 Open filing 4
WONG RODERICK 10% ownerSeries A Preferred Stock Derivative security · underlying Common Stock0I See footnoteAs of 2026-04-20 Open filing 4
WONG RODERICK 10% ownerSeries B Preferred Stock Derivative security · underlying Common Stock0I See footnoteAs of 2026-04-20 Open filing 4
WONG RODERICK 10% ownerCommon Stock 10,776,820I See footnoteAs of 2026-04-20 Open filing 4
Wasserman Scott M. Officer: Chief Medical OfficerStock Option (right to buy) Derivative security · underlying Common Stock100,000D As of 2026-04-16 Open filing 4

Joint filers each report the same shares, so rows are not added together.

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.

Showing 1–50 of 132

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
Bain Capital Investors LLC 26,255,581 SH299,838,735 dollarsUnchanged Prior quarter: 26,255,581Open filing 0001193125-26-462000 Filed 2026-11-16 Dispute this row
Bain Capital Life Sciences Investors, LLC 22,583,268 SH257,900,921 dollarsUnchanged Prior quarter: 22,583,268Open filing 0001193125-26-462089 Filed 2026-11-16 Dispute this row
RTW INVESTMENTS, LP 10,776,820 SH123,071,284 dollarsUnchanged Prior quarter: 10,776,820Open filing 0001493215-26-000214 Filed 2026-11-16 Dispute this row
CANADA PENSION PLAN INVESTMENT BOARD 7,304,688 SH83,419,537 dollarsUnchanged Prior quarter: 7,304,688Open filing 0001104659-26-128255 Filed 2026-11-16 Dispute this row
Atlas Venture Life Science Advisors, LLC 5,171,282 SH59,056,040 dollarsUnchanged Prior quarter: 5,171,282Open filing 0001104659-26-125242 Filed 2026-11-10 Dispute this row
FMR LLC Partly reported under another manager4,659,885 SH53,215,889 dollarsHigher by 689,020 Prior quarter: 3,970,865Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
BlackRock, Inc. Partly reported under another manager4,573,014 SH52,223,817 dollarsHigher by 644,410 Prior quarter: 3,928,604Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
ADAGE CAPITAL PARTNERS GP, L.L.C. 4,173,720 SH47,663,882 dollarsHigher by 965,434 Prior quarter: 3,208,286Open filing 0001172661-26-005200 Filed 2026-11-16 Dispute this row
CITADEL ADVISORS LLC Partly reported under another manager3,648,133 SH41,661,679 dollarsHigher by 407,346 Prior quarter: 3,240,787Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
Royalty Pharma Sub-Manager, LLC Partly reported under another manager2,455,357 SH28,040,177 dollarsUnchanged Prior quarter: 2,455,357Open filing 0002081668-26-000021 Filed 2026-11-13 Dispute this row
STATE STREET CORP Partly reported under another manager2,241,320 SH25,595,874 dollarsHigher by 1,373,160 Prior quarter: 868,160Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
Siren, L.L.C. Partly reported under another manager2,214,286 SH25,287,146 dollarsUnchanged Prior quarter: 2,214,286Open filing 0002005245-26-000013 Filed 2026-11-12 Dispute this row
AMERIPRISE FINANCIAL INC Partly reported under another manager2,094,262 SH23,916,506 dollarsHigher by 1,272,931 Prior quarter: 821,331Open filing 0001193125-26-463125 Filed 2026-11-16 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 1,681,786 SH19,205,996 dollarsLower by 12,172 Prior quarter: 1,693,958Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC 1,619,874 SH18,498,961 dollarsLower by 32,633 Prior quarter: 1,652,507Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager1,206,848 SH13,785,325 dollarsHigher by 73,733 Prior quarter: 1,133,115Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
Frazier Life Sciences Management, L.P. 1,200,000 SH13,704,000 dollarsHigher by 100,000 Prior quarter: 1,100,000Open filing 0001892134-26-000007 Filed 2026-11-16 Dispute this row
FARALLON CAPITAL MANAGEMENT, L.L.C. 1,100,000 SH12,562,000 dollarsUnchanged Prior quarter: 1,100,000Open filing 0000908834-26-000540 Filed 2026-11-16 Dispute this row
Trails Edge Capital Partners, LP 942,953 SH10,768,523 dollarsLower by 41,833 Prior quarter: 984,786Open filing 0002077247-26-000005 Filed 2026-11-16 Dispute this row
MARSHALL WACE, LLP Partly reported under another manager878,196 SH10,028,997 dollarsNot in the prior quarter’s filings read Open filing 0001318757-26-000012 Filed 2026-11-13 Dispute this row
MILLENNIUM MANAGEMENT LLC 858,972 SH9,809,460 dollarsNot in the prior quarter’s filings read Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row
GOLDMAN SACHS GROUP INC Partly reported under another manager696,577 SH7,954,909 dollarsHigher by 275,543 Prior quarter: 421,034Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row
PRICE T ROWE ASSOCIATES INC /MD/ Partly reported under another manager631,951 SH7,218 dollarsLower by 2,902,459 Prior quarter: 3,534,410Open filing 0000080255-26-000736 Filed 2026-11-16 Dispute this row
Vestal Point Capital, LP 625,000 SH7,137,500 dollarsHigher by 50,000 Prior quarter: 575,000Open filing 0001974915-26-000008 Filed 2026-11-16 Dispute this row
UBS Group AG Partly reported under another manager469,584 SH5,362,649 dollarsLower by 503,099 Prior quarter: 972,683Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
Catalio Capital Management, LP 468,750 SH5,353,125 dollarsUnchanged Prior quarter: 468,750Open filing 0001958125-26-000012 Filed 2026-11-16 Dispute this row
Aberdeen Group plc Partly reported under another manager432,661 SH4,940,989 dollarsHigher by 292,661 Prior quarter: 140,000Open filing 0001716774-26-000032 Filed 2026-11-10 Dispute this row
Walleye Capital LLC 416,853 SH4,760,461 dollarsNot in the prior quarter’s filings read Open filing 0001758720-26-000007 Filed 2026-11-13 Dispute this row
BANK OF AMERICA CORP /DE/ Partly reported under another manager408,261 SH4,662,341 dollarsHigher by 351,751 Prior quarter: 56,510Open filing 0000070858-26-000589 Filed 2026-11-16 Dispute this row
FEDERATED HERMES, INC. Partly reported under another manager403,693 SH4,610,174 dollarsLower by 30,376 Prior quarter: 434,069Open filing 0001623632-26-001675 Filed 2026-11-12 Dispute this row
FRANKLIN TEMPLETON INC Partly reported under another manager401,443 SH5,138,470 dollarsHigher by 1,420 Prior quarter: 400,023Open filing 0000038777-26-000291 Filed 2026-11-12 Dispute this row
Cormorant Asset Management, LP Partly reported under another manager400,000 SH4,568,000 dollarsLower by 150,000 Prior quarter: 550,000Open filing 0001583977-26-000011 Filed 2026-11-16 Dispute this row
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 384,636 SH4,392,543 dollarsHigher by 21,726 Prior quarter: 362,910Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row
Jump Financial, LLC Partly reported under another manager381,002 SH4,351,042 dollarsNot in the prior quarter’s filings read Open filing 0000905148-26-004786 Filed 2026-11-13 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager361,395 SH4,127,131 dollarsHigher by 6,964 Prior quarter: 354,431Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
Janus Henderson Group Ltd. Partly reported under another manager345,848 SH3,949,584 dollarsNot in the prior quarter’s filings read Open filing 0001085146-26-000952 Filed 2026-11-16 Dispute this row
BNP PARIBAS FINANCIAL MARKETS Partly reported under another manager310,269 SH3,543,272 dollarsHigher by 303,269 Prior quarter: 7,000Open filing 0001166588-26-000012 Filed 2026-11-12 Dispute this row
VANGUARD FIDUCIARY TRUST CO 290,142 SH3,313,422 dollarsHigher by 14 Prior quarter: 290,128Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
WELLINGTON MANAGEMENT GROUP LLP Partly reported under another manager271,912 SH3,105,235 dollarsLower by 2,647,198 Prior quarter: 2,919,110Open filing 0000902219-26-000323 Filed 2026-11-16 Dispute this row
EXCHANGE TRADED CONCEPTS, LLC Partly reported under another manager260,799 SH2,978,325 dollarsHigher by 108,298 Prior quarter: 152,501Open filing 0001213900-26-113173 Filed 2026-10-28 Dispute this row
Point72 Asset Management, L.P. 230,115 SH2,627,913 dollarsNot in the prior quarter’s filings read Open filing 0000919574-26-008126 Filed 2026-11-16 Dispute this row
XTX Topco Ltd Partly reported under another manager228,447 SH2,608,865 dollarsHigher by 179,223 Prior quarter: 49,224Open filing 0001828301-26-000009 Filed 2026-11-16 Dispute this row
RENAISSANCE TECHNOLOGIES LLC Partly reported under another manager198,549 SH2,267,430 dollarsNot in the prior quarter’s filings read Open filing 0001037389-26-000062 Filed 2026-11-12 Dispute this row
SEVEN GRAND MANAGERS, LLC 175,000 SH1,998,500 dollarsUnchanged Prior quarter: 175,000Open filing 0001420506-26-002775 Filed 2026-11-16 Dispute this row
ALPS ADVISORS INC 171,739 SH1,961,259 dollarsHigher by 40,739 Prior quarter: 131,000Open filing 0001398344-26-019318 Filed 2026-11-03 Dispute this row
MORGAN STANLEY Partly reported under another manager155,399 SH1,774,657 dollarsHigher by 97,613 Prior quarter: 57,786Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
HRT FINANCIAL LP 151,000 SH1,724 dollarsNot in the prior quarter’s filings read Open filing 0001475597-26-000249 Filed 2026-11-13 Dispute this row
Nuveen, LLC Partly reported under another manager147,192 SH1,680,932 dollarsHigher by 58,396 Prior quarter: 88,796Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row
Bank of New York Mellon Corp Partly reported under another manager140,934 SH1,609,466 dollarsHigher by 2,535 Prior quarter: 138,399Open filing 0001390777-26-000121 Filed 2026-11-05 Dispute this row
a16z Capital Management, L.L.C. 140,000 SH1,598,800 dollarsUnchanged Prior quarter: 140,000Open filing 0001540358-26-000014 Filed 2026-11-16 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • Jupiter Topco LLC 970,857 SH
  • Deep Track Capital, LP 700,000 SH
  • EVENTIDE ASSET MANAGEMENT, LLC 616,720 SH
  • Sixth Street Partners Management Company, L.P. 362,910 SH
  • TD Asset Management Inc 147,698 SH
  • Avidity Partners Management LP 80,000 SH
  • Foresite Capital Management VI LLC 37,500 SH
  • Universal- Beteiligungs- und Servicegesellschaft mbH 22,951 SH
  • SOROS FUND MANAGEMENT LLC 20,000 SH
  • D. E. Shaw Co., Inc. 17,500 SH
  • Harbour Capital Advisors, LLC 16,570 SH
  • VICTORY CAPITAL MANAGEMENT INC 10,306 SH
  • Hudson Bay Capital Management LP 10,050 SH
  • GABELLI FUNDS LLC 10,000 SH
  • Penserra Capital Management LLC 4,864 SH
  • DIADEMA PARTNERS LP 3,621 SH
  • Persistent Asset Partners Ltd 1,765 SH
  • Fortitude Family Office, LLC 32 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text; they are read only when their rows add up to the totals the filer states.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Institutional ownership reported on Form 13F

13F filers report holding between 63.70% and 92.19% of shares outstanding.

Quarter ending 2026-09-30, against 129,850,481 shares on the cover dated 2026-10-29.

  • The lower figure counts positions a manager reports as its own with sole discretion. The upper figure counts every plain-share position and can count a share twice.
  • Neither includes holders that do not file Form 13F, or managers below the filing threshold.
Quarter-by-quarter 13F holders
QuarterManagers holdingShares, at leastShares, at mostFilings read
2026-09-30 13282,715,849119,706,9288,935
2026-06-30 10281,895,810117,385,6569,178
2026-03-31 0009,173
2025-12-31 0009,222
2025-09-30 0008,469
2025-06-30 0008,516
2025-03-31 0008,518
2024-12-31 0008,580

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read from their tags. Earlier schedules are free text: they are read only when every cover page states a share count and a percent, and the rest are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
CPP Investment Board Private Holdings (4) Inc. Common Stock, $0.00001 par value per share5.67,304,68806/30/2026 Filed 2026-08-14SCHEDULE 13GOpen filing 0001193125-26-352133 Dispute this row
Canada Pension Plan Investment Board Common Stock, $0.00001 par value per share5.67,304,68806/30/2026 Filed 2026-08-14SCHEDULE 13GOpen filing 0001193125-26-352133 Dispute this row
RTW Investments, LP Common Stock, $0.00001 par value8.310,776,820.0006/30/2026 Filed 2026-08-14SCHEDULE 13GOpen filing 0001493215-26-000151 Dispute this row
Roderick Wong Common Stock, $0.00001 par value8.310,776,820.0006/30/2026 Filed 2026-08-14SCHEDULE 13GOpen filing 0001493215-26-000151 Dispute this row
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Common Stock, $0.00001 par value per share8.911,511,853.0006/30/2026 Filed 2026-08-05SCHEDULE 13GOpen filing 0001104659-26-090642 Dispute this row
BCLS Fund IV Investments, L.P. Common Stock, $0.00001 par value per share17.4322,583,26804/16/2026 Filed 2026-04-23SCHEDULE 13DOpen filing 0001193125-26-174330 Dispute this row
BCPE Perseus Investor, LP Common Stock, $0.00001 par value per share20.2726,255,58104/16/2026 Filed 2026-04-23SCHEDULE 13DOpen filing 0001193125-26-174293 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

3,104,499 filings read, dated 1980-01-02 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015258,595
2016246,472
2017244,814
2018245,575
2019238,619
2020249,093
2021274,850
2022257,922
2023253,676
2024261,106
2025235,525
2026263,830

Filings made before the SEC required XML are listed, not extracted.

Back to Kailera Therapeutics, Inc.